Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986393 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| Arm A: BMS-986393 + Alnuctamab | EXPERIMENTAL | - |
| Arm B: BMS-986393 + Mezigdomide | EXPERIMENTAL | - |
| Arm C: BMS-986393 + Iberdomide | EXPERIMENTAL | - |
| Arm D: BMS-986393 + Elranatamab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986393 | DRUG | Specified dose on specified days |
| Cyclophosphamide | DRUG | Specified dose on specified days |
| Fludarabine | DRUG | Specified dose on specified days |
| Daratumumab | DRUG | Specified dose on specified days |
| Pomalidomide | DRUG | Specified dose on specified days |
| Dexamethasone | DRUG | Specified dose on specified days |
| Carfilzomib | DRUG | Specified dose on specified days |
| Alnuctamab | DRUG | Specified dose on specified days |
| Mezigdomide | DRUG | Specified dose on specified days |
| Iberdomide | DRUG | Specified dose on specified days |
| Elranatamab | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have relapsed or refractory multiple myeloma (RRMM). * Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monocl...
Top 20 of 25 competitors
BMS-986393 is an investigational therapy being studied for the treatment of multiple myeloma, including relapsed or refractory multiple myeloma (RRMM). It is being evaluated in clinical trials for adult participants with this blood cancer.
BMS-986393 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and effectiveness in multiple myeloma.
BMS-986393 is in clinical development, with trials in Phase 1 and Phase 3. The Phase 1 trial is studying the drug in novel combinations, while the Phase 3 trial, called QUINTESSENTIAL-2, compares it to standard regimens in relapsed or refractory multiple myeloma.
BMS-986393 is being studied in two clinical trials. NCT06121843 is a Phase 1 trial evaluating the drug in combinations for relapsed and/or refractory multiple myeloma. NCT06615479 is the Phase 3 QUINTESSENTIAL-2 trial comparing BMS-986393 to standard regimens in lenalidomide-exposed multiple myeloma.
Yes, BMS-986393 is also known as Arlocabtagene Autoleucel. The Phase 1 clinical trial NCT06121843 uses this alternative name in its title, confirming that both names refer to the same investigational drug.
BMS-986393 is not FDA approved. It is an investigational drug currently in clinical development, with active trials in Phase 1 and Phase 3 for multiple myeloma. Its safety and effectiveness have not yet been established for commercial use.